I hear you, I do wonder who will put their hand up for another CR only to find out yet another "ah...we should have made it this and that"
That's just how it reads - it obviously works, I believe in the science but this is can't keep happening, CLBP will hopefully provide a boon for investors, at least enough to stick around.
I hope Novartis takes over trial design and other parts of the non-covid19 ARDS trial - time to inject some confidence. Maybe a management shake-up or even a buy-out at the current cheap price.
Oh well...who knows.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-625
-
- There are more pages in this discussion • 451 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |